People & Positions

We are aware that this decision represents a drastic change for the employees at the Hamburg site, says Maximilian Morin, who is responsible for the Care Solutions business line. The decision was made after intensive evaluations of various options and represents the best solution for the successful development of the business." We are aware of the importance of the site for our employees and for the region. At the same time, we have the responsibility to ensure the long-term competitiveness of our business," says Emmanuel Auer, head of the Smart Effects business line, which the chlorosilane business is part of."

And this week, I'm going to give you a taste of some of the very cool stuff five of them are working on, which includes lifesaving innovations and groundbreaking age reversal" tech. Preventing maternal deaths Let's start with Paschal Kija, a 28-year-old who has developed a device to treat postpartum hemorrhage—a dangerous birth complication that contributes to around 29% of maternal deaths in his home country, Tanzania. Inspired by kirigami—the traditional Japanese art of cutting paper to form three-dimensional shapes—she's created a sheet of electrodes with a honeycombed structure shaped like a spiral basket. Reversing the aging process to treat eye disease The buzziest tech in longevity right now centers on reprogramming—attempts to rewind the age of cells by resetting them to a more embryonic-like state."

Queen's University Belfast, as part of a seven-institution all-island ageing research network, has received funding to train future health professional leaders across the island of Ireland. The Irish Clinical Academic Training-Accelerating Health Research to Support Ageing Demographics (ICAT-AHEAD) Programme, received a funding boost from Wellcome. The programme will be led by Professor Bernadette McGuinness from the School of Medicine, Dentistry and Biomedical Sciences at Queen's University Belfast, working in partnership with RCSI University of Medicine and Health Sciences, Trinity College Dublin, Ulster University, University College Cork, the University of Galway and University College Dublin.

Marc Stegger fra Statens Serum Institut (SSI) blev fredag tildelt årets forskningslegat fra Professor dr.med. Fritz Kauffmanns Forskningsfond på baggrund af sin stærke akademiske profil og mangeårige forskningsindsats inden for mikrobielle patogener og antibiotikaresistens. Marc Steggers forskning har blandt andet bidraget til udviklingen af genombaserede metoder og en national infrastruktur for mikrobielle sekvensdata, som kan understøtte diagnostik, overvågning og forskning. Forskningslegatet gives til støtte for Marc Steggers fortsatte forskning og skal blandt andet bidrage til, at han kan videreudvikle sine forskningsområder og udbygge de samarbejder, der kendetegner hans arbejde. Det betyder meget for mig, at fonden ønsker at støtte den forskning, jeg har arbejdet med gennem mange år, og som jeg håber kan være med til at gøre en forskel i vores forståelse af infektionssygdomme og mulige behandlinger, siger Marc Stegger."

He previously held senior scientific and clinical leadership positions at the University of Maryland School of Medicine, where he was Professor of Medicine, Microbiology, and Immunology and Chief of Infectious Diseases. He will help strengthen the scientific foundation of GX-03, facilitate in the design of our studies and shape where our platform should go next." Dr. Redfield will work closely with Burnam, Stephen M. Hahn, M.D., Turn Therapeutics Executive Clinical and Regulatory Lead and former Commissioner of the U.S. Food and Drug Administration, and the Company's clinical investigators and scientific advisors. Forward-looking statements are based on Turn's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the success of development programs, the availability of additional financing, and the Company's ability to execute its strategic plan. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company's filings with the SEC."